6,292 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,292 shares of the company's stock, valued at approximately $283,000.

Other institutional investors have also recently made changes to their positions in the company. TimesSquare Capital Management LLC purchased a new stake in Soleno Therapeutics during the fourth quarter worth $15,273,000. Vanguard Group Inc. grew its stake in Soleno Therapeutics by 19.2% in the fourth quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after purchasing an additional 303,806 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in Soleno Therapeutics by 48.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 851,838 shares of the company's stock worth $38,290,000 after purchasing an additional 276,225 shares in the last quarter. Emerald Advisers LLC lifted its position in shares of Soleno Therapeutics by 85.4% during the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after buying an additional 267,585 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Soleno Therapeutics by 14.5% in the 4th quarter. Wellington Management Group LLP now owns 782,265 shares of the company's stock valued at $35,163,000 after buying an additional 99,095 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SLNO shares. Guggenheim reissued a "buy" rating and set a $81.00 target price (up previously from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. Robert W. Baird increased their price objective on Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a report on Thursday, March 27th. Piper Sandler boosted their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Laidlaw increased their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. Finally, UBS Group set a $105.00 price target on Soleno Therapeutics in a research note on Thursday, March 27th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $104.67.

Insider Buying and Selling at Soleno Therapeutics

In related news, VP Michael F. Huang sold 14,583 shares of Soleno Therapeutics stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the completion of the transaction, the vice president now directly owns 36,817 shares in the company, valued at approximately $2,559,149.67. This trade represents a 28.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This represents a 54.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 942,672 shares of company stock worth $64,058,781. Insiders own 12.30% of the company's stock.

Soleno Therapeutics Stock Up 0.0 %

Shares of NASDAQ:SLNO traded up $0.03 during trading on Thursday, hitting $74.89. The stock had a trading volume of 146,406 shares, compared to its average volume of 725,931. Soleno Therapeutics, Inc. has a 12-month low of $36.93 and a 12-month high of $76.56. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of -22.64 and a beta of -2.29. The stock has a 50-day simple moving average of $59.07 and a two-hundred day simple moving average of $53.31.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41). As a group, sell-side analysts forecast that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.